Journal of Geriatric Psychiatry and Neurology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burn, D. J.
Right arrow Articles by Tröster, A. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burn, D. J.
Right arrow Articles by Tröster, A. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Geriatric Psychiatry and Neurology, Vol. 17, No. 3, 172-180 (2004)
DOI: 10.1177/0891988704267466

Neuropsychiatric Complications of Medical and Surgical Therapies for Parkinson’s Disease

David J. Burn, MD, FRCP

Regional Neurosciences Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BEd.j.burn{at}ncl.ac.uk

Alexander I. Tröster, PhD

Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

This review deals with the range of neuropsychiatric problems that may arise from the use of medical and surgical therapies in the treatment of Parkinson’s disease. As new approaches emerge, these problems are diversifying. Well-recognized drug-related complications include hallucinations and psychosis and the so-called dopamine-dysregulation syndrome. The etiology of these problems has not been fully established and is not clearly dose related, while the management can be difficult and needs to be tailored to the individual patient. Cholinergic and dopaminergic drugs may both influence cognitive function. The development of pharmacogenetics could improve the therapeutic ratio of medical approaches to PD in the future. The literature relating to the neuropsychiatric issues complicating the surgical treatment of Parkinson’s disease is more recent and frequently suffers from methodological problems, lack of a systematic approach, and adequate patient follow-up. The emergence of neuropsychiatric problems in association with surgery has shed new light upon the pathophysiological mechanisms underpinning these symptoms. Depression, hypo-mania, euphoria, mirth, and hypersexuality have all been described following deep brain stimulation procedures, although most studies have concentrated upon the depressive features. Anxiety has been described only rarely to date. Fortunately, permanent cognitive complications appear to be rare. The optimal management approach for surgically related neuropsychiatric problems is unknown at present. Prospective multicenter studies would contribute significantly to resolving this therapeutic uncertainty. (J Geriatr Psychiatry Neurol 2004; 17:172-180)

Key Words: Parkinson’s disease • medical and surgical therapies

References

  • 1. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology 1995; 45:1757-1760.[Abstract/Free Full Text]
  • 2. Jenkins RB, Groh RH. Mental symptoms in parkinsonian patients treated with L-dopa. Lancet 1970; 2:177-180.[CrossRef][Medline] [Order article via Infotrieve]
  • 3. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123:733-745.[Abstract/Free Full Text]
  • 4. Barnes J, David AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001; 70:727-733.[Abstract/Free Full Text]
  • 5. Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson’s disease: a community-based study. Arch Neurol 1999; 56:595-601.[Abstract/Free Full Text]
  • 6. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. Eur J Neurol 1999; 6:S17-S23.[CrossRef]
  • 7. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesias in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342:1484-1491.[Abstract/Free Full Text]
  • 8. Parkinson’s Study Group. Pramipexole vs levodopa as initial treatment for Parkinson’s disease. JAMA 2000; 284:1931-1938.[Abstract/Free Full Text]
  • 9. Oertel WH. Pergolide vs levodopa (PELMOPET). Mov Disord 2000; 15:4-4.
  • 10. Poewe W. Psychosis in Parkinson’s disease. Mov Disord 2003; 18:S80-S87.
  • 11. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998; 50:515-517.[Abstract]
  • 12. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998; 51:811-814.[Abstract/Free Full Text]
  • 13. Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain 1992; 115:1701-1725.[Abstract/Free Full Text]
  • 14. Bédard MA, Pillon B, Dubois B, et al. Acute and long-term administration of anticholinergics in Parkinson’s disease: specific effects on the subcortico-frontal syndrome. Brain Cog 1999; 40:289-313.[CrossRef][Medline] [Order article via Infotrieve]
  • 15. Pondal M, Del Ser T, Bermejo F. Anticholinergic therapy and dementia in patients with Parkinson’s disease. J Neurol 1996; 243:543-546.[CrossRef][Medline] [Order article via Infotrieve]
  • 16. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol 2003; 54:235-238.[CrossRef][Medline] [Order article via Infotrieve]
  • 17. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson’s disease. Drugs Aging 2000; 16:365-379.[CrossRef][Medline] [Order article via Infotrieve]
  • 18. Costa A, Peppe A, Dell’Agnello G, et al. Dopaminergic modulation of visual-spatial working memory in Parkinson’s disease. Dement Geriatr Cogn Disord 2003; 15:55-66.[CrossRef][Medline] [Order article via Infotrieve]
  • 19. Cools R, Stefanova E, Barker RA, et al. Dopaminergic modulation of high-level cognition in Parkinson’s disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125:584-594.[Abstract/Free Full Text]
  • 20. Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical function in patients with Parkinson’s disease. Ann Neurol 2002; 51:156-164.[CrossRef][Medline] [Order article via Infotrieve]
  • 21. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropsychologia 2003; 41:1431-1441.[CrossRef][Medline] [Order article via Infotrieve]
  • 22. Kurlan R, Dimitsopulos T. Selegiline and manic behavior in Parkinson’s disease. Arch Neurol 1992; 49:1231-1231.[Medline] [Order article via Infotrieve]
  • 23. Riley DE. Reversible transvestic fetishism in a man with Parkinson’s disease treated with selegiline. Clin Neuropharmacol 2002; 25:234-237.[CrossRef][Medline] [Order article via Infotrieve]
  • 24. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson’s disease: reward systems gone awry? Lancet Neurology 2003; 2:595-604.
  • 25. Sanchez-Ramos J. The straight dope on addiction to dopaminergic drugs. Mov Disord 2002; 17:223-225.[Medline] [Order article via Infotrieve]
  • 26. Giovannoni G, O’Sullivan JD, Turner K, et al. Hedonistic home-ostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68:423-428.[Abstract/Free Full Text]
  • 27. Koob GF, Le Moal M. Drug abuse: hedonistic homeostatic dysregulation. Science 1997; 278:52-57.[Abstract/Free Full Text]
  • 28. Freed C, Greene P, Breze W, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001; 344:710-719.[Abstract/Free Full Text]
  • 29. Siegfried J, Blond S. The neurosurgical treatment of Parkinson’s disease and other movement disorders. London: Williams & Wilkins Europe, 1997.
  • 30. Wilkinson SB, Tröster AI. Surgical interventions in neurodegenerative disease: impact on memory and cognition. In: Tröster AI, ed. Memory in neurodegenerative disease: biological, cognitive, and clinical perspectives. Cambridge, UK: Cambridge University Press, 1998:362-376.
  • 31. Tröster AI, Fields JA. The role of neuropsychological evaluation in the neurosurgical treatment of movement disorders. In: Tarsy D, Vitek JL, Lozano AM, eds. Surgical treatment of Parkinson’s disease and other movement disorders. Totowa, NJ: Humana, 2003:213-240.
  • 32. Koller W, Hristova A. Efficacy and safety of stereotaxic surgical treatment of tremor disorders. Eur J Neurol 1996; 3:507-514.
  • 33. Laitinen LV. Behavioral complications of early pallidotomy. Brain Cogn 2000; 42:313-323.[CrossRef][Medline] [Order article via Infotrieve]
  • 34. Jurko MF, Andy OJ. Electrical and behavioral changes following thalamotomy. Surg Forum 1961; 12:404-406.[Medline] [Order article via Infotrieve]
  • 35. Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease. Mov Disord 2003; 18:1332-1337.[CrossRef][Medline] [Order article via Infotrieve]
  • 36. Diederich NJ, Alesch F, Goetz CG. Visual hallucinations induced by deep brain stimulation in Parkinson’s disease. Clin Neuropharmacol 2000; 23:287-289.[CrossRef][Medline] [Order article via Infotrieve]
  • 37. Lagrange E, Krack P, Moro E, et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 2002; 59:1976-1978.[Abstract/Free Full Text]
  • 38. Berney A, Vingerhoets F, Perrin A, et al. Effect on mood of subthalamic DBS for Parkinson’s disease: a consecutive series of 24 patients. Neurology 2002; 59:1427-1429.[Abstract/Free Full Text]
  • 39. Narabayashi H, Miyashita N, Hattori Y, et al. Posteroventral pallidotomy: its effect on motor symptoms and scores of MMPI test in patients with Parkinson’s disease. Parkinsonism Relat Disord 1997; 3:7-20.
  • 40. Hays P, Krikler B, Walsh LS, Woolfson G. Psychological changes following surgical treatment of parkinsonism. Am J Psychiatry 1966; 123:657-663.[Abstract/Free Full Text]
  • 41. Lund-Johansen M, Hugdahl K, Wester K. Cognitive function in patients with Parkinson’s disease undergoing stereotaxic thalamotomy. J Neurol Neurosurg Psychiatry 1996; 60:564-571.[Abstract]
  • 42. Intemann PM, Masterman D, Subramanian I, et al. Staged bilateral pallidotomy for treatment of Parkinson disease. J Neurosurg 2001; 94:437-444.[Medline] [Order article via Infotrieve]
  • 43. Martínez-Martín P, Valldeoriola F, Molinuevo JL, et al. Pallidotomy and quality of life in patients with Parkinson’s disease: an early study. Mov Disord 2000; 15:65-70.[CrossRef][Medline] [Order article via Infotrieve]
  • 44. Masterman D, DeSalles A, Baloh RW, et al. Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson disease. Arch Neurol 1998; 55:1201-1208.[Abstract/Free Full Text]
  • 45. Rettig GM, York MK, Lai EC, et al. Neuropsychological out-come after unilateral pallidotomy for the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000; 69:326-336.[Abstract/Free Full Text]
  • 46. Riordan HJ, Flashman LA, Roberts DW. Neurocognitive and psychosocial correlates of ventroposterolateral pallidotomy surgery in Parkinson’s disease [electronic manuscript]. Neurosurg Focus 1997; 2:e7-e7.[Medline] [Order article via Infotrieve]
  • 47. Schmand B, de Bie RM, Koning-Haanstra M, et al. Unilateral pallidotomy in PD: a controlled study of cognitive and behavioral effects. The Netherlands Pallidotomy Study (NEPAS) group. Neurology 2000; 54:1058-1064.[Abstract/Free Full Text]
  • 48. Straits-Tröster K, Fields JA, Wilkinson SB, et al. Health-related quality of life in Parkinson’s disease after pallidotomy and deep brain stimulation. Brain Cogn 2000; 42:399-416.[CrossRef][Medline] [Order article via Infotrieve]
  • 49. Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson’s disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996; 40:355-366.[CrossRef][Medline] [Order article via Infotrieve]
  • 50. Cahn DA, Sullivan EV, Shear PK, et al. Neuropsychological and motor functioning after unilateral anatomically guided posterior ventral pallidotomy. Preoperative performance and three-month follow-up. Neuropsychiatry Neuropsychol Behav Neurol 1998; 11:136-145.[Medline] [Order article via Infotrieve]
  • 51. Scott R, Gregory R, Hines N, et al. Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson’s disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures. Brain 1998; 121:659-675.[Abstract/Free Full Text]
  • 52. Kubu CS, Grace GM, Parrent AG. Cognitive outcome following pallidotomy: the influence of side of surgery and age of patient at disease onset. J Neurosurg 2000; 92:384-389.[Medline] [Order article via Infotrieve]
  • 53. Perrine K, Dogali M, Fazzini E, et al. Cognitive functioning after pallidotomy for refractory Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 65:150-154.[Abstract/Free Full Text]
  • 54. Trépanier LL, Kumar R, Lozano AM, et al. Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson’s disease. Brain Cogn 2000; 42:324-347.[CrossRef][Medline] [Order article via Infotrieve]
  • 55. Uitti RJ, Wharen RE, Duffy JR, et al. Unilateral pallidotomy for Parkinson’s disease: speech, motor, and neuropsychological out-come measurements. Parkinsonism Relat Disord 2000; 6:133-143.[CrossRef][Medline] [Order article via Infotrieve]
  • 56. Bezerra MLS, Martinez J-VL, Nasser JA.Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 1999; 341:1003-1004.[Free Full Text]
  • 57. Ghika J, Ghika-Schmid F, Fankhauser H, et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson’s disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. J Neurosurg 1999; 91:313-321.[Medline] [Order article via Infotrieve]
  • 58. Patel NK, Heywood P, O’Sullivan K, et al. Unilateral subthalamotomy in the treatment of Parkinson’s disease. Brain 2003; 126:1136-1145.[Abstract/Free Full Text]
  • 59. Caparros-Lefebvre D, Blond S, Pécheux N, et al. Evaluation neuropsychologique avant et après stimulation thalamique chez 9 parkinsoniens. Rev Neurol (Paris) 1992; 148:117-122.[Medline] [Order article via Infotrieve]
  • 60. Ardouin C, Pillon B, Peiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson’s disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol 1999; 46:217-223.[CrossRef][Medline] [Order article via Infotrieve]
  • 61. Ghika J, Villemure JG, Fankhauser H, et al. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson’s disease with severe motor fluctuations: a 2-year follow-up review. J Neurosurg 1998; 89:713-718.[Medline] [Order article via Infotrieve]
  • 62. Vingerhoets G, van der Linden C, Lannoo E, et al. Cognitive out-come after unilateral pallidal stimulation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 66:297-304.[Abstract/Free Full Text]
  • 63. Benabid AL, Koudsié A, Benazzouz A, et al. Deep brain stimulation of the corpus luysi (subthalamic nucleus) and other targets in Parkinson’s disease. Extension to new indications such as dystonia and epilepsy. J Neurol 2001; 248(suppl 3):37-47.[CrossRef]
  • 64. Ostergaard K, Sunde N, Dupont E. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson’s disease and motor fluctuations. Mov Disord 2002; 17:693-700.[CrossRef][Medline] [Order article via Infotrieve]
  • 65. Kleiner-Fisman G, Fisman DN, Sime E, et al. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 2003; 99:489-495.[Medline] [Order article via Infotrieve]
  • 66. Doshi PK, Chhaya N, Bhatt MH. Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson’s disease. Mov Disord 2002; 17:1084-1085.[CrossRef][Medline] [Order article via Infotrieve]
  • 67. Martínez-Martín P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson’s disease. Mov Disord 2002; 17:372-377.[CrossRef][Medline] [Order article via Infotrieve]
  • 68. Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson’s disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72:701-707.[Abstract/Free Full Text]
  • 69. Thobois S, Mertens P, Guenot M, et al. Subthalamic nucleus stimulation in Parkinson’s disease: clinical evaluation of 18 patients. J Neurol 2002; 249:529-534.[CrossRef][Medline] [Order article via Infotrieve]
  • 70. Daniele A, Albanese A, Contarino MF, et al. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003; 74:175-182.[Abstract/Free Full Text]
  • 71. Bejjani BP, Damier P, Arnulf I, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 1999; 340:1476-1480.[Free Full Text]
  • 72. Stefurak T, Mikulis D, Mayberg H, et al. Deep brain stimulation for Parkinson’s disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord 2003; 18:1508-1516.[CrossRef][Medline] [Order article via Infotrieve]
  • 73. Okun MS, Green J, Saben R, et al. Mood changes with deep brain stimulation of STN and GPi: results of a pilot study. J Neurol Neurosurg Psychiatry 2003; 74:1584-1586.[Abstract/Free Full Text]
  • 74. Funkiewiez A, Ardouin C, Krack P, et al.Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson’s disease. Mov Disord 2003; 18:524-530.[CrossRef][Medline] [Order article via Infotrieve]
  • 75. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 2003; 349:1925-1934.[Abstract/Free Full Text]
  • 76. Burn DJ. Depression in Parkinson’s disease. Eur J Neurol 2002; 9(suppl 3):44-54.
  • 77. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67:492-496.[Abstract/Free Full Text]
  • 78. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003; 54:403-414.[CrossRef][Medline] [Order article via Infotrieve]
  • 79. Perozzo P, Rizzone M, Bergamasco B, et al. Deep brain stimulation of subthalamic nucleus: behavioural modifications and familiar relations. Neurol Sci 2001; 22:81-82.[CrossRef][Medline] [Order article via Infotrieve]
  • 80. Tröster AI, Letsch EA. Anxiety and depression. In: Pahwa R, Lyons KE, Koller WC, eds. Therapy of Parkinson’s disease. 3rd ed. New York: Marcel Dekker, 2004:423-445.
  • 81. Okun MS, Bakay RA, DeLong MR, Vitek JL. Transient manic behavior after pallidotomy. Brain Cogn 2003; 52:281-283.[CrossRef][Medline] [Order article via Infotrieve]
  • 82. Miyawaki E, Perlmutter JS,Tröster AI, et al.The behavioral complications of pallidal stimulation: a case report. Brain Cogn 2000; 42:417-434.[CrossRef][Medline] [Order article via Infotrieve]
  • 83. Herzog J, Reiff J, Krack P, et al. Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson’s disease. Mov Disord 2003; 18:1382-1384.[CrossRef][Medline] [Order article via Infotrieve]
  • 84. Romito LM, Scerrati M, Contarino MF, et al. Long-term follow up of subthalamic nucleus stimulation in Parkinson’s disease. Neurology 2002; 58:1546-1550.[Abstract/Free Full Text]
  • 85. Kulisevsky J, Berthier ML, Gironell A, et al. Mania following deep brain stimulation for Parkinson’s disease. Neurology 2002; 59:1421-1424.[Abstract/Free Full Text]
  • 86. Higginson CI, Fields JA, Tröster AI. Which symptoms of anxiety diminish after surgical interventions for Parkinson’s disease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14:117-121.[Medline] [Order article via Infotrieve]
  • 87. Fields JA, Tröster AI, Wilkinson SB, et al. Cognitive outcome following staged bilateral pallidal stimulation for the treatment of Parkinson’s disease. Clin Neurol Neurosurg 1999; 101:182-188.[CrossRef][Medline] [Order article via Infotrieve]
  • 88. Junqué C, Alegret M, Nobbe FA, et al. Cognitive and behavioral changes after unilateral posteroventral pallidotomy: relationship with lesional data from MRI. Mov Disord 1999; 14:780-789.[CrossRef][Medline] [Order article via Infotrieve]
  • 89. Hays P, Krikler B, Walsh LS, et al. Psychological changes following surgical treatment of parkinsonism. Am J Psychiatry 1966; 123:657-663.
  • 90. Woods SP, Fields JA, Tröster AI. Neuropsychological sequelae of subthalamic nucleus deep brain stimulation in Parkinson’s disease: a critical review. Neuropsychol Rev 2002; 12:111-126.[CrossRef][Medline] [Order article via Infotrieve]
  • 91. de Bie RM, de Haan RJ, Schuurman PR, et al. Morbidity and mortality following pallidotomy in Parkinson’s disease: a systematic review. Neurology 2002; 58:1008-1012.[Abstract/Free Full Text]
  • 92. Broggi G, Dones I, Ferroli P, et al. Surgery for movement disorders: complications and complication avoidance. Semin Neurosurg 2001; 12:225-231.[CrossRef]
  • 93. Tröster AI,Woods SP, Fields JA, et al. Declines in switching under-lie verbal fluency changes after unilateral pallidal surgery in Parkinson’s disease. Brain Cogn 2002; 50:207-217.[CrossRef][Medline] [Order article via Infotrieve]
  • 94. Saint-Cyr JA, Trépanier LL, Kumar R, et al. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson’s disease. Brain 2000; 123:2091-2108.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
D Aarsland, K Bronnick, U Ehrt, P P De Deyn, S Tekin, M Emre, and J L Cummings
Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress
J. Neurol. Neurosurg. Psychiatry, January 1, 2007; 78(1): 36 - 42.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burn, D. J.
Right arrow Articles by Tröster, A. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burn, D. J.
Right arrow Articles by Tröster, A. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?